179 related articles for article (PubMed ID: 25910639)
1. Functional-segregated coumarin-containing telodendrimer nanocarriers for efficient delivery of SN-38 for colon cancer treatment.
Xu G; Shi C; Guo D; Wang L; Ling Y; Han X; Luo J
Acta Biomater; 2015 Jul; 21():85-98. PubMed ID: 25910639
[TBL] [Abstract][Full Text] [Related]
2. Fine-tuning vitamin E-containing telodendrimers for efficient delivery of gambogic acid in colon cancer treatment.
Huang W; Wang X; Shi C; Guo D; Xu G; Wang L; Bodman A; Luo J
Mol Pharm; 2015 Apr; 12(4):1216-29. PubMed ID: 25692376
[TBL] [Abstract][Full Text] [Related]
3. Novel lipophilic SN38 prodrug forming stable liposomes for colorectal carcinoma therapy.
Xing J; Zhang X; Wang Z; Zhang H; Chen P; Zhou G; Sun C; Gu N; Ji M
Int J Nanomedicine; 2019; 14():5201-5213. PubMed ID: 31371956
[No Abstract] [Full Text] [Related]
4. Sub-100nm, long tumor retention SN-38-loaded photonic micelles for tri-modal cancer therapy.
Yang X; Xue X; Luo Y; Lin TY; Zhang H; Lac D; Xiao K; He Y; Jia B; Lam KS; Li Y
J Control Release; 2017 Sep; 261():297-306. PubMed ID: 28700898
[TBL] [Abstract][Full Text] [Related]
5. Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors.
Koizumi F; Kitagawa M; Negishi T; Onda T; Matsumoto S; Hamaguchi T; Matsumura Y
Cancer Res; 2006 Oct; 66(20):10048-56. PubMed ID: 17047068
[TBL] [Abstract][Full Text] [Related]
6. A novel size-tunable nanocarrier system for targeted anticancer drug delivery.
Li Y; Xiao K; Luo J; Lee J; Pan S; Lam KS
J Control Release; 2010 Jun; 144(3):314-23. PubMed ID: 20211210
[TBL] [Abstract][Full Text] [Related]
7. Biodegradable Polymeric Micelle-Mediated Delivery of a pH-Activatable Prodrug of 7-Ethyl-10-Hydroxy-Camptothecin (SN-38) to Enhance Anti-Angiogenesis and Anti-Tumor Activity.
Song L; Zeng A; Hu M; Lin Y; Shu Y; Huang X; Gong C; Xie Y; Wu Q
J Biomed Nanotechnol; 2018 Feb; 14(2):267-280. PubMed ID: 31352923
[TBL] [Abstract][Full Text] [Related]
8. Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion.
Kalra AV; Kim J; Klinz SG; Paz N; Cain J; Drummond DC; Nielsen UB; Fitzgerald JB
Cancer Res; 2014 Dec; 74(23):7003-13. PubMed ID: 25273092
[TBL] [Abstract][Full Text] [Related]
9. Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer.
Neijzen R; Wong MQ; Gill N; Wang H; Karim T; Anantha M; Strutt D; Waterhouse D; Bally MB; Tai IT; Ng SS; Yapp DT
J Control Release; 2015 Feb; 199():72-83. PubMed ID: 25497312
[TBL] [Abstract][Full Text] [Related]
10. Smart AS1411-aptamer conjugated pegylated PAMAM dendrimer for the superior delivery of camptothecin to colon adenocarcinoma in vitro and in vivo.
Alibolandi M; Taghdisi SM; Ramezani P; Hosseini Shamili F; Farzad SA; Abnous K; Ramezani M
Int J Pharm; 2017 Mar; 519(1-2):352-364. PubMed ID: 28126548
[TBL] [Abstract][Full Text] [Related]
11. Tumour regression and improved gastrointestinal tolerability from controlled release of SN-38 from novel polyoxazoline-modified dendrimers.
England RM; Hare JI; Barnes J; Wilson J; Smith A; Strittmatter N; Kemmitt PD; Waring MJ; Barry ST; Alexander C; Ashford MB
J Control Release; 2017 Feb; 247():73-85. PubMed ID: 28043863
[TBL] [Abstract][Full Text] [Related]
12. SN38 polymeric nanoparticles: in vitro cytotoxicity and in vivo antitumor efficacy in xenograft balb/c model with breast cancer versus irinotecan.
Sepehri N; Rouhani H; Tavassolian F; Montazeri H; Khoshayand MR; Ghahremani MH; Ostad SN; Atyabi F; Dinarvand R
Int J Pharm; 2014 Aug; 471(1-2):485-97. PubMed ID: 24879937
[TBL] [Abstract][Full Text] [Related]
13. Development and characterization of pH responsive polymeric nanoparticles of SN-38 for colon cancer.
Prasad S; Dangi JS
Artif Cells Nanomed Biotechnol; 2016 Dec; 44(8):1824-1834. PubMed ID: 26540095
[TBL] [Abstract][Full Text] [Related]
14. Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models.
Zamboni WC; Stewart CF; Cheshire PJ; Richmond LB; Hanna SK; Luo X; Poquette C; McGovren JP; Houghton JA; Houghton PJ
Clin Cancer Res; 1998 Mar; 4(3):743-53. PubMed ID: 9533544
[TBL] [Abstract][Full Text] [Related]
15. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
[TBL] [Abstract][Full Text] [Related]
16. CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates.
Govindan SV; Cardillo TM; Moon SJ; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2009 Oct; 15(19):6052-61. PubMed ID: 19789330
[TBL] [Abstract][Full Text] [Related]
17. Enhanced therapeutic efficacy of a novel liposome-based formulation of SN-38 against human tumor models in SCID mice.
Lei S; Chien PY; Sheikh S; Zhang A; Ali S; Ahmad I
Anticancer Drugs; 2004 Sep; 15(8):773-8. PubMed ID: 15494639
[TBL] [Abstract][Full Text] [Related]
18. Development of thermosensitive poly(n-isopropylacrylamide-co-((2-dimethylamino) ethyl methacrylate))-based nanoparticles for controlled drug release.
Peng CL; Tsai HM; Yang SJ; Luo TY; Lin CF; Lin WJ; Shieh MJ
Nanotechnology; 2011 Jul; 22(26):265608. PubMed ID: 21576795
[TBL] [Abstract][Full Text] [Related]
19. Potential oral delivery of 7-ethyl-10-hydroxy-camptothecin (SN-38) using poly(amidoamine) dendrimers.
Kolhatkar RB; Swaan P; Ghandehari H
Pharm Res; 2008 Jul; 25(7):1723-9. PubMed ID: 18438703
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo evaluation of SN-38 nanocrystals with different particle sizes.
Chen M; Li W; Zhang X; Dong Y; Hua Y; Zhang H; Gao J; Zhao L; Li Y; Zheng A
Int J Nanomedicine; 2017; 12():5487-5500. PubMed ID: 28814865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
